Testicular function of survivors of childhood cancer: A comparative study between ifosfamide- and cyclophosphamide-based regimens

被引:44
作者
Ridola, Vita [1 ,2 ]
Fawaz, Oumaya [1 ]
Aubier, Francoise [3 ]
Bergeron, Christophe [4 ]
de Vathaire, Florent [5 ]
Pichon, Fabienne [6 ]
Orbach, Daniel [7 ]
Gentet, Jean Claude [8 ]
Schmitt, Claudine [9 ]
Dufour, Christelle [1 ]
Oberlin, Odile [1 ]
机构
[1] Inst Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France
[2] Univ Cattolica Sacro Cuore, Dept Pediat Oncol, Rome, Italy
[3] Ctr Therapeut, Dept Oncol, Margency, France
[4] Ctr Leon Berard, Dept Pediat Oncol, F-69373 Lyon, France
[5] INSERM, U605, Villejuif, France
[6] Ctr Oscar Lambret, Dept Pediat, F-59020 Lille, France
[7] Inst Curie, Dept Pediat Oncol, Paris, France
[8] Univ Hosp La Timone, Dept Pediat Oncol, Marseille, France
[9] Univ Hosp, Dept Hematol & Oncol, Nancy, France
关键词
Ifosfamide; Cyclophosphamide; Fertility; Male; Toxicity; Gonads; Long-term sequelae; MALE GONADAL-FUNCTION; HODGKINS-DISEASE; PEDIATRIC ONCOLOGY; CHEMOTHERAPY; ADOLESCENCE; THERAPY; SARCOMA; DAMAGE; RHABDOMYOSARCOMA; OSTEOSARCOMA;
D O I
10.1016/j.ejca.2009.01.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study aimed at comparing gonadal toxicity of ifosfamide versus cyclophosphamide received during childhood. Methods: The evaluation was based on basal FSH measurement. LH and testosterone were also measured in most of the patients. One hundred patients had received ifosfamide and 59 had received cyclophosphamide. Results: Median age at treatment was 11.2 years. The median interval since treatment was 10.7 years (range 4.1-20.2) and median age at evaluation was 21.4 years (17.5-36.1). The median dose of ifosfamide and of cyclophosphamide was 54 g/m(2) (18-114) and 8.3 g/m(2) (4.6-22), respectively. All but two males had normal testosterone levels. FSH was abnormal in 28/59 patients (47.5%) after receiving cyclophosphamide and was within the normal range in 94/100 patients (94%) after receiving ifosfamide. Conclusions: These results show that ifosfamide is associated with a lower risk of gonadal damage than cyclophosphamide. The risk of abnormal FSH increased with the cumulative dose of cyclophosphamide. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:814 / 818
页数:5
相关论文
共 35 条
  • [1] MALE GONADAL-FUNCTION AFTER CHEMOTHERAPY FOR SOLID TUMORS IN CHILDHOOD
    AUBIER, F
    FLAMANT, F
    BRAUNER, R
    CAILLAUD, JM
    CHAUSSAIN, JM
    LEMERLE, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (03) : 304 - 309
  • [2] AUBIER F, 1995, ANN ENDOCRINOL-PARIS, V56, P141
  • [3] Ben Arush MW, 2000, PEDIATR HEMAT ONCOL, V17, P239
  • [4] COMPARATIVE ACTIVITY OF IFOSFAMIDE AND CYCLOPHOSPHAMIDE
    BRADE, W
    SEEBER, S
    HERDRICH, K
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1986, 18 : S1 - S9
  • [5] BRAMSWIG JH, 1990, CANCER-AM CANCER SOC, V65, P1298, DOI 10.1002/1097-0142(19900315)65:6<1298::AID-CNCR2820650607>3.0.CO
  • [6] 2-W
  • [7] Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease
    Crist, WM
    Anderson, JR
    Meza, JL
    Fryer, C
    Raney, RB
    Ruymann, FB
    Breneman, J
    Qualman, SJ
    Wiener, E
    Wharam, M
    Lobe, T
    Webber, B
    Maurer, HM
    Donaldson, SS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) : 3091 - 3102
  • [8] Treatment of non-metastatic rhabdomyosarcomas in childhood and adolescence. Results of the second study of the International Society of Paediatric Oncology: MMT84
    Flamant, F
    Rodary, C
    Rey, A
    Praquin, MT
    Sommelet, D
    Quintana, E
    Theobald, S
    Brunat-Mentigny, M
    Otten, J
    Voute, PA
    Habrand, JL
    Martelli, H
    Barrett, A
    Terrier-Lacombe, MJ
    Oberlin, O
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 (07) : 1050 - 1062
  • [9] Progress in the development of childhood cancer therapy
    Garolla, Andrea
    Pizzato, Cristina
    Ferlin, Alberto
    Carli, Modesto Ottaviano
    Selice, Riccardo
    Foresta, Carlo
    [J]. REPRODUCTIVE TOXICOLOGY, 2006, 22 (02) : 126 - 132
  • [10] Heikens J, 1996, CANCER, V78, P2020, DOI 10.1002/(SICI)1097-0142(19961101)78:9<2020::AID-CNCR25>3.0.CO